
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma Inc. shows a promising outlook primarily due to its innovative approach in developing BB-301, a therapeutic for Oculopharyngeal Muscular Dystrophy, with interim clinical results indicating a 100% responder rate and the potential for long-term improvement in patient outcomes. The recent data suggests increased interactions with regulators that could lead to accelerated market entry, alongside favorable pricing opportunities reflecting the treatment's value thanks to demonstrated efficacy. Additionally, Benitec's robust financial position, with $94.5 million in cash and cash equivalents, positions the company well to support the ongoing development and potential regulatory pathways for BB-301.
Bears say
Benitec Biopharma reported a net loss of $0.21 per share for the first quarter of fiscal 2026, a smaller loss than anticipated, primarily attributed to a higher-than-expected number of shares outstanding. The company faces significant risks, including the potential for slower-than-expected clinical trial progress for its BB-301 treatment, negative trial data, and challenges in establishing a regulatory approval pathway. Additionally, there are concerns regarding slow market adoption and long-term dilution risks, which contribute to a cautious financial outlook for the company.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares